产品
编 号：F492417
分子式：C21H26N6O2
分子量：394.47
分子式：C21H26N6O2
分子量：394.47
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
2mg
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 875320-29-9
产品详情
生物活性：
Quisinostat (JNJ-26481585) is a potent, second-generation and orally active pan-HDAC inhibitor (HDACi), with IC50 values ranging from 0.11 nM to 0.64 nM for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11. Quisinostat has a broad spectrum antitumoral activity. Quisinostat can induce autophagy in neuroblastoma cells.
体内研究：
Quisinostat (40 mg/kg; p.o.; once daily; for 3 days) acts as a potent HDAC1 inhibitor that inhibits p21waf1,cip1 ZsGreen tumors in vivo.?Quisinostat induces continuous H3 acetylation in tumor tissue in vivo.?Quisinostat (10 mg/kg; once daily; i.p.; for 14 days) strongly inhibits the growth of large pre-established HCT116 colon xenografts.Animal Model:NMRI nude mice, with HCT116 colon carcinoma cells xenografts
Dosage:10 mg/kg
Administration:Intraperitoneal injection, once daily, for 14 days
Result:Strongly inhibited the growth of large pre-established HCT116 colon xenografts.
体外研究：
Quisinostat inhibits HDAC isozymes in vitro.?Quisinostat (30-1000 nM; 24 hours) is a potent pan-HDAC inhibitor in tumor cells.?Quisinostat has a broad spectrum antiproliferative activity against solid and hematologic cancer cell lines and induces apoptosis.
Quisinostat (JNJ-26481585) is a potent, second-generation and orally active pan-HDAC inhibitor (HDACi), with IC50 values ranging from 0.11 nM to 0.64 nM for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11. Quisinostat has a broad spectrum antitumoral activity. Quisinostat can induce autophagy in neuroblastoma cells.
体内研究：
Quisinostat (40 mg/kg; p.o.; once daily; for 3 days) acts as a potent HDAC1 inhibitor that inhibits p21waf1,cip1 ZsGreen tumors in vivo.?Quisinostat induces continuous H3 acetylation in tumor tissue in vivo.?Quisinostat (10 mg/kg; once daily; i.p.; for 14 days) strongly inhibits the growth of large pre-established HCT116 colon xenografts.Animal Model:NMRI nude mice, with HCT116 colon carcinoma cells xenografts
Dosage:10 mg/kg
Administration:Intraperitoneal injection, once daily, for 14 days
Result:Strongly inhibited the growth of large pre-established HCT116 colon xenografts.
体外研究：
Quisinostat inhibits HDAC isozymes in vitro.?Quisinostat (30-1000 nM; 24 hours) is a potent pan-HDAC inhibitor in tumor cells.?Quisinostat has a broad spectrum antiproliferative activity against solid and hematologic cancer cell lines and induces apoptosis.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备